2Zabransky RJ,Heights S. Linezolid: the first of a new class of antimicrobial agents[J]. Clin Microb Newslett, 2002, 24 (4) :25-30.
3Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: com- parator-controlled phase Ⅲ studies [ J ]. Antimicrob Agents Chemother, 2003,47 (6) : 1824-1831.
4Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, Grampositive infec- tions: experience from a compassionate-use program [ J ]. Clin Infect Dis, 2003,36( 15 ) : 159-68.
5Attassi K, Hershberger E, Alam R, et al. Thrombocytope- nia associated with linezolid therapy [ J ]. Clin Infect Dis, 2002,34( 1 ) :695-698.
6Orrick JJ, Johns T, Janelle J, et al. Thrombocytopenia sec- ondary to linezolid administration: what is the risk? [J] Clin Infect Dis, 2002,35 : 348-349.
7Wu VC, Wang YT, Wang CY, et al. High frequency of lin- ezolid-associated thrombocytopenia and anemia among pa- tients with end-stage renal disease [ J ]. Clin Infect Dis, 2006,42:66-72.
8Matsumoto K,Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in pa- tients with renal dysfunction [ J ]. International Journal of Antimicrobial Agents, 2010, (36) : 179-181.
9Matsumoto K, Takeda Y, Takeshita A, et al. Renal func-tion as a predictor of linezolid-induced thrombocytopenia [ J]. Int J Antimicrob Agents, 2009,33:98-99.
10Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability[J]. Journal of Infection, 2009, 59 (S1) : S59- S74.
